Variable influence of mutational patterns in reverse-transcriptase domain on replication capacity of hepatitis B virus isolates from antiviral-experienced patients (Q43659537)

From Wikidata

Jump to navigation Jump to search

scientific article published on November 5, 2010

Language	Label	Description	Also known as
English	Variable influence of mutational patterns in reverse-transcriptase domain on replication capacity of hepatitis B virus isolates from antiviral-experienced patients	scientific article published on November 5, 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Variable influence of mutational patterns in reverse-transcriptase domain on replication capacity of hepatitis B virus isolates from antiviral-experienced patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Hepatitis B virus

1 reference

based on heuristic

inferred from title

1

object named as

Dong Ji

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21056552

22 August 2024

author name string

Yan Liu

2

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Lan-Lan Si

3

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Le Li

4

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Guo-Feng Chen

5

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Shao-Jie Xin

6

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Jin-Min Zhao

7

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Dongping Xu

8

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21056552

22 August 2024

publication date

5 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

full work available at URL

https://api.elsevier.com/content/article/PII:S0009898110006807?httpAccept=text/xml

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

https://api.elsevier.com/content/article/PII:S0009898110006807?httpAccept=text/plain

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Clinica Chimica Acta

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

412

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

3-4

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

305-313

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Monitoring during and after antiviral therapy for hepatitis B.

1

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Hepatitis B: the virus and disease

2

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Chronic hepatitis B: who to treat and which choice of treatment?

3

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Hepatitis B treatment: Current best practices, avoiding resistance.

4

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach

5

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

6

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

7

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials

8

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Detection of the rtA181V/T and rtN236T mutations associated with resistance to adefovir dipivoxil using a ligase detection reaction assay

9

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

10

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present

11

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response

12

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B

13

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Antiviral resistance and hepatitis B therapy

14

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro

15

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.

16

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Real-time PCR quantitation of hepatitis B virus total DNA and covalently closed circular DNA in peripheral blood mononuclear cells from hepatitis B virus-infected patients

17

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Hepatitis B virus resistance to nucleos(t)ide analogues.

18

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Variant of hepatitis B virus with primary resistance to adefovir

19

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Primary infection with a lamivudine-resistant hepatitis B virus

21

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Ultrasensitive genotypic detection of antiviral resistance in hepatitis B virus clinical isolates

22

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Naturally occurring amino-acid substitutions to nucleos(t)ide analogues in treatment naive Turkish patients with chronic hepatitis B.

23

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Prevalence and clinical characterization of patients with acute hepatitis B induced by lamivudine-resistant strains

25

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

In vitro models for studying hepatitis B virus drug resistance

26

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients

27

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing.

28

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B

30

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Hepatitis B virus genotype and basal core promoter/precore mutations are associated with hepatitis B-related acute-on-chronic liver failure without pre-existing liver cirrhosis

31

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Features and clinical implications of hepatitis B virus genotypes and mutations in basal core promoter/precore region in 507 Chinese patients with acute and chronic hepatitis B.

32

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Replication of duck hepatitis B virus in two differentiated human hepatoma cell lines after transfection with cloned viral DNA.

33

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Simultaneous quantitation and genotyping of hepatitis B virus by real-time PCR and melting curve analysis

34

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Sensitive and accurate quantitation of hepatitis B virus DNA using a kinetic fluorescence detection system (TaqMan PCR).

35

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label s

36

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Hepatitis B virus variants

37

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Effect of basal core promoter and pre-core mutations on hepatitis B virus replication.

38

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Molecular characterization of a variant virus that caused de novo hepatitis B without elevation of hepatitis B surface antigen after chemotherapy with rituximab

39

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Nucleic acid testing for viral burden and viral genotyping

41

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene

42

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient.

43

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Identification of HBV DNA sequences that are predictive of response to lamivudine therapy

44

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome.

46

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

In vitro characterization of viral fitness of therapy-resistant hepatitis B variants

47

1 reference

10.1016/J.CCA.2010.10.028

https://api.crossref.org/works/10.1016/J.CCA.2010.10.028

22 August 2024

Identifiers

10.1016/J.CCA.2010.10.028

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43659537&oldid=2233473466"